- Home
- CPD Activities
- A real-world intention-to-treat analysis of a decade’s experience of treatment of hepatitis C with interferon-based therapies
A real-world intention-to-treat analysis of a decade’s experience of treatment of hepatitis C with interferon-based therapies
Name | World Continuing Education Alliance |
Activity Title | A real-world intention-to-treat analysis of a decade’s experience of treatment of hepatitis C with interferon-based therapies |
Details | Data from the World Health Organization suggest that 130–150 million people are infected with chronic hepatitis C worldwide, a significant proportion of whom will develop liver cirrhosis or cancer. There are seven known genotypes of HCV, although it is possible for patients to be infected with more than one genotype concurrently. Until 2011, the only approved treatment option for patients infected with HCV was a pegylated interferon (PegIFN) plus ribavirin (RBV)-based regimen administered for 48 weeks for genotype 1, and 24 weeks for genotypes 2 and 3. Sustained virological response (SVR) rates reported in the registration studies for the dual therapy, PegIFN plus RBV, were 42–52% for genotype 1 and 76–88% for genotypes 2 and 3. In 2011, two first-generation protease inhibitors, telaprevir and boceprevir, were licensed for use alongside PegIFN plus RBV for patients with HCV genotype 1. This triple therapy improved SVR rates for genotype 1 patients from 42–52% to 66–75%. Although patien...
Objectives
Course Objective
To assess the uptake of pegylated interferon (PegIFN) plus ribavirin (RBV)-based regimens in patients with hepatitis C virus (HCV) in a large, single-centre, real-world setting over 10 years.. This was a single centre, retrospective analysis of data from patients who attended their first appointment for treatment of HCV genotype 1–3 between 2003 and 2013. Patients were stratified by HCV genotype. The total number of patients who attended their first appointment, incidence of patients who did not proceed to treatment and associated reasons, and incidence of patients treated were analysed. |
Competence | Public Health |
Start Date | <span class="not-set">(not set)</span> |
End Date | <span class="not-set">(not set)</span> |
Event Time | 01:15 PM |
Location | World Continuing Education Alliance eLearning System |
Cost (UGX) | 0 |
CPD Points | 1 |
---|